Implantation of Hypoxia-Induced Mesenchymal Stem Cell Advances Therapeutic Angiogenesis

Overview

Journal Stem Cells Int

Publisher Wiley

Specialty Cell Biology

Date 2022 Mar 31

PMID 35355589

Authors

Farina Mohamad Yusoff

Ayumu Nakashima

Ki-Ichiro Kawano

Masato Kajikawa

Shinji Kishimoto

Tatsuya Maruhashi

Naoki Ishiuchi

S Fadilah S Abdul Wahid

Yukihito Higashi

Affiliations

Soon will be listed here.

Abstract

Hypoxia preconditioning enhances the paracrine abilities of mesenchymal stem cells (MSCs) for vascular regeneration and tissue healing. Implantation of hypoxia-induced mesenchymal stem cells (hi-MSCs) may further improve limb perfusion in a murine model of hindlimb ischemia. This study is aimed at determining whether implantation of hi-MSCs is an effective modality for improving outcomes of treatment of ischemic artery diseases. We evaluated the effects of human bone marrow-derived MSC implantation on limb blood flow in an ischemic hindlimb model. hi-MSCs were prepared by cell culture under 1% oxygen for 24 hours prior to implantation. A total of 1 × 10 MSCs and hi-MSCs and phosphate-buffered saline (PBS) were intramuscularly implanted into ischemic muscles at 36 hours after surgery. Restoration of blood flow and muscle perfusion was evaluated by laser Doppler perfusion imaging. Blood perfusion recovery, enhanced vessel densities, and improvement of function of the ischemia limb were significantly greater in the hi-MSC group than in the MSC or PBS group. Immunochemistry revealed that hi-MSCs had higher expression levels of hypoxia-inducible factor-1 alpha and vascular endothelial growth factor A than those in MSCs. In addition, an endothelial cell-inducing medium showed high expression levels of vascular endothelial growth factor, platelet endothelial cell adhesion molecule-1, and von Willebrand factor in hi-MSCs compared to those in MSCs. These findings suggest that pretreatment of MSCs with a hypoxia condition and implantation of hi-MSCs advances neovascularization capability with enhanced therapeutic angiogenic effects in a murine hindlimb ischemia model.

Citing Articles

Glucocorticoids in lung cancer: Navigating the balance between immunosuppression and therapeutic efficacy.

Xu W, Ye J, Cao Z, Zhao Y, Zhu Y, Li L Heliyon. 2024; 10(12):e32357.

PMID: 39022002 PMC: 11252876. DOI: 10.1016/j.heliyon.2024.e32357.

Hypoxia-preconditioned bone marrow-derived mesenchymal stem cells protect neurons from cardiac arrest-induced pyroptosis.

Tang X, Zheng N, Lin Q, You Y, Gong Z, Zhuang Y Neural Regen Res. 2024; 20(4):1103-1123.

PMID: 38845218 PMC: 11438345. DOI: 10.4103/NRR.NRR-D-23-01922.

Application of hypoxia-mesenchymal stem cells in treatment of anaerobic bacterial wound infection: wound healing and infection recovery.

Andalib E, Kashfi M, Mahmoudvand G, Rezaei E, Mahjoor M, Torki A Front Microbiol. 2023; 14:1251956.

PMID: 37869672 PMC: 10586055. DOI: 10.3389/fmicb.2023.1251956.

A Supportive Role of Mesenchymal Stem Cells on Insulin-Producing Langerhans Islets with a Specific Emphasis on The Secretome.

Sionov R, Ahdut-HaCohen R Biomedicines. 2023; 11(9).

PMID: 37761001 PMC: 10527322. DOI: 10.3390/biomedicines11092558.

Mesenchymal Stem/Stromal Cells for Therapeutic Angiogenesis.

Yusoff F, Higashi Y Cells. 2023; 12(17).

PMID: 37681894 PMC: 10486439. DOI: 10.3390/cells12172162.

References

Isner J, Asahara T . Angiogenesis and vasculogenesis as therapeutic strategies for postnatal neovascularization. J Clin Invest. 1999; 103(9):1231-6. PMC: 408362. DOI: 10.1172/JCI6889. View

Yusoff F, Kajikawa M, Matsui S, Hashimoto H, Kishimoto S, Maruhashi T . Review of the Long-term Effects of Autologous Bone-Marrow Mononuclear Cell Implantation on Clinical Outcomes in Patients with Critical Limb Ischemia. Sci Rep. 2019; 9(1):7711. PMC: 6531470. DOI: 10.1038/s41598-019-44176-5. View

Archacka K, Grabowska I, Mierzejewski B, Graffstein J, Gorzynska A, Krawczyk M . Hypoxia preconditioned bone marrow-derived mesenchymal stromal/stem cells enhance myoblast fusion and skeletal muscle regeneration. Stem Cell Res Ther. 2021; 12(1):448. PMC: 8351116. DOI: 10.1186/s13287-021-02530-3. View

Matoba S, Tatsumi T, Murohara T, Imaizumi T, Katsuda Y, Ito M . Long-term clinical outcome after intramuscular implantation of bone marrow mononuclear cells (Therapeutic Angiogenesis by Cell Transplantation [TACT] trial) in patients with chronic limb ischemia. Am Heart J. 2008; 156(5):1010-8. DOI: 10.1016/j.ahj.2008.06.025. View

Lee J, Yoon Y, Lee S . Hypoxic Preconditioning Promotes the Bioactivities of Mesenchymal Stem Cells via the HIF-1α-GRP78-Akt Axis. Int J Mol Sci. 2017; 18(6). PMC: 5486141. DOI: 10.3390/ijms18061320. View

Lambertini E, Penolazzi L, Angelozzi M, Scussel Bergamin L, Manferdini C, Vieceli Dalla Sega F . Hypoxia Preconditioning of Human MSCs: a Direct Evidence of HIF-1α and Collagen Type XV Correlation. Cell Physiol Biochem. 2018; 51(5):2237-2249. DOI: 10.1159/000495869. View

Pignon B, Sevestre M, Kanagaratnam L, Pernod G, Stephan D, Emmerich J . Autologous Bone Marrow Mononuclear Cell Implantation and Its Impact on the Outcome of Patients With Critical Limb Ischemia　- Results of a Randomized, Double-Blind, Placebo-Controlled Trial. Circ J. 2017; 81(11):1713-1720. DOI: 10.1253/circj.CJ-17-0045. View

Higashi Y, Yusoff F, Kishimoto S, Maruhashi T . Regenerative medicine for radiation emergencies. J Radiat Res. 2021; 62(Supplement_1):i21-i29. PMC: 8114226. DOI: 10.1093/jrr/rraa091. View

Hsueh W, Gupte A . PGC-1α: the missing ingredient for mesenchymal stem cell-mediated angiogenesis. Diabetes. 2012; 61(5):979-80. PMC: 3331752. DOI: 10.2337/db12-0078. View

10.

Behroozian A, Beckman J . Microvascular Disease Increases Amputation in Patients With Peripheral Artery Disease. Arterioscler Thromb Vasc Biol. 2020; 40(3):534-540. DOI: 10.1161/ATVBAHA.119.312859. View

11.

Hirota K, Semenza G . Regulation of angiogenesis by hypoxia-inducible factor 1. Crit Rev Oncol Hematol. 2006; 59(1):15-26. DOI: 10.1016/j.critrevonc.2005.12.003. View

12.

Almeria C, Weiss R, Roy M, Tripisciano C, Kasper C, Weber V . Hypoxia Conditioned Mesenchymal Stem Cell-Derived Extracellular Vesicles Induce Increased Vascular Tube Formation . Front Bioeng Biotechnol. 2019; 7:292. PMC: 6819375. DOI: 10.3389/fbioe.2019.00292. View

13.

Higashi Y, Noma K, Yoshizumi M, Kihara Y . Endothelial function and oxidative stress in cardiovascular diseases. Circ J. 2009; 73(3):411-8. DOI: 10.1253/circj.cj-08-1102. View

14.

Oswald J, Boxberger S, Jorgensen B, Feldmann S, Ehninger G, Bornhauser M . Mesenchymal stem cells can be differentiated into endothelial cells in vitro. Stem Cells. 2004; 22(3):377-84. DOI: 10.1634/stemcells.22-3-377. View

15.

Asahara T, Murohara T, Sullivan A, Silver M, van der Zee R, Li T . Isolation of putative progenitor endothelial cells for angiogenesis. Science. 1997; 275(5302):964-7. DOI: 10.1126/science.275.5302.964. View

16.

Ejtehadifar M, Shamsasenjan K, Movassaghpour A, Akbarzadehlaleh P, Dehdilani N, Abbasi P . The Effect of Hypoxia on Mesenchymal Stem Cell Biology. Adv Pharm Bull. 2015; 5(2):141-9. PMC: 4517092. DOI: 10.15171/apb.2015.021. View

17.

Farber A . Chronic Limb-Threatening Ischemia. N Engl J Med. 2018; 379(2):171-180. DOI: 10.1056/NEJMcp1709326. View

18.

Samura M, Hosoyama T, Takeuchi Y, Ueno K, Morikage N, Hamano K . Therapeutic strategies for cell-based neovascularization in critical limb ischemia. J Transl Med. 2017; 15(1):49. PMC: 5324309. DOI: 10.1186/s12967-017-1153-4. View

19.

Cooke J, Losordo D . Modulating the vascular response to limb ischemia: angiogenic and cell therapies. Circ Res. 2015; 116(9):1561-78. PMC: 4869986. DOI: 10.1161/CIRCRESAHA.115.303565. View

20.

Duff S, Mafilios M, Bhounsule P, Hasegawa J . The burden of critical limb ischemia: a review of recent literature. Vasc Health Risk Manag. 2019; 15:187-208. PMC: 6617560. DOI: 10.2147/VHRM.S209241. View